BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37014824)

  • 1. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
    Roopkumar J; Poudel SK; Gervaso L; Reddy CA; Velcheti V; Pennell NA; McCrae KR; Khorana AA
    J Thromb Haemost; 2021 Mar; 19(3):822-829. PubMed ID: 33314597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of venous thromboembolism among patients with primary lung cancer.
    Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
    J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Recurrent Venous Thromboembolism or Arterial Thrombotic Events during and after Anticoagulation for a First Venous Thromboembolism.
    Noumegni SR; Tromeur C; Hoffmann C; Mao RL; Moigne EL; Moreuil C; Mansourati V; Nasr B; Gentric JC; Guegan M; Poulhazan E; Bressollette L; Lacut K; Didier R; Couturaud F
    Semin Thromb Hemost; 2023 Oct; 49(7):688-701. PubMed ID: 36252603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma.
    Kaptein FHJ; Stals MAM; Kapteijn MY; Cannegieter SC; Dirven L; van Duinen SG; van Eijk R; Huisman MV; Klaase EE; Taphoorn MJB; Versteeg HH; Buijs JT; Koekkoek JAF; Klok FA
    J Thromb Haemost; 2022 Jul; 20(7):1665-1673. PubMed ID: 35460331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Qian X; Fu M; Zheng J; Zhou J; Zhou J
    Front Oncol; 2021; 11():680191. PubMed ID: 33996610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
    Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
    J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
    Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
    Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and Timing of Venous Thromboembolism After Surgery for Lung Cancer: A Nationwide Cohort Study.
    Mørkved AL; Søgaard M; Skjøth F; Ording AG; Jensen M; Larsen TB; Jakobsen E; Højen AA; Noble S; Meldgaard P; Petersen RH; Christensen TD
    Ann Thorac Surg; 2024 Feb; 117(2):289-296. PubMed ID: 37890818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
    Gulati S; Hsu CY; Shah S; Shah PK; Zon R; Alsamarai S; Awosika J; El-Bakouny Z; Bashir B; Beeghly A; Berg S; de-la-Rosa-Martinez D; Doroshow DB; Egan PC; Fein J; Flora DB; Friese CR; Fromowitz A; Griffiths EA; Hwang C; Jani C; Joshi M; Khan H; Klein EJ; Heater NK; Koshkin VS; Kwon DH; Labaki C; Latif T; McKay RR; Nagaraj G; Nakasone ES; Nonato T; Polimera HV; Puc M; Razavi P; Ruiz-Garcia E; Saliby RM; Shastri A; Singh SRK; Tagalakis V; Vilar-Compte D; Weissmann LB; Wilkins CR; Wise-Draper TM; Wotman MT; Yoon JJ; Mishra S; Grivas P; Shyr Y; Warner JL; Connors JM; Shah DP; Rosovsky RP;
    JAMA Oncol; 2023 Oct; 9(10):1390-1400. PubMed ID: 37589970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea.
    Yhim HY; Lee J; Kim KH; Kim SA; Lee JY; Hwang HG; Hong J; Lee JO; Bang SM
    Thromb Res; 2023 Nov; 231():50-57. PubMed ID: 37804738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
    He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
    Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
    Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
    J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Previously undiagnosed cancer in patients with arterial thrombotic events - A population-based cohort study.
    Leader A; Dagan N; Barda N; Goldberg I; Raanani P; Spectre G; Balicer R; Gafter-Gvili A
    J Thromb Haemost; 2022 Mar; 20(3):635-647. PubMed ID: 34818468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous and arterial thromboembolism after colorectal cancer in the Netherlands: Incidence, predictors, and prognosis.
    Anijs RJS; Chen Q; van der Hulle T; Versteeg HH; Klok FA; Lijfering WM; Cannegieter SC
    Thromb Res; 2023 Sep; 229():90-98. PubMed ID: 37421683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System.
    Martens KL; Li A; La J; May SB; Swinnerton KN; Tosi H; Elbers DC; Do NV; Brophy MT; Gaziano JM; Lotfollahzadeh S; Chitalia V; Ravid K; Fillmore NR
    JAMA Netw Open; 2023 Jun; 6(6):e2317945. PubMed ID: 37306999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
    Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
    J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma.
    Davidsson E; Murgia N; Ortiz-Villalón C; Wiklundh E; Sköld M; Kölbeck KG; Ferrara G
    Multidiscip Respir Med; 2017; 12():16. PubMed ID: 28560038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.